176 related articles for article (PubMed ID: 9003953)
1. Serum alpha L-fucosidase enzyme activity in ovarian and other female genital tract tumors.
Abdel-Aleem H; Ahmed A; Sabra AM; Zakhari M; Soliman M; Hamed H
Int J Gynaecol Obstet; 1996 Dec; 55(3):273-9. PubMed ID: 9003953
[TBL] [Abstract][Full Text] [Related]
2. Value of the serum alpha-L-fucosidase activity in the diagnosis of colorectal cancer.
Ayude D; Fernández-Rodríguez J; Rodríguez-Berrocal FJ; Martínez-Zorzano VS; de Carlos A; Gil E; Páez de La Cadena M
Oncology; 2000 Nov; 59(4):310-6. PubMed ID: 11096343
[TBL] [Abstract][Full Text] [Related]
3. Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma.
Giardina MG; Matarazzo M; Varriale A; Morante R; Napoli A; Martino R
Cancer; 1992 Sep; 70(5):1044-8. PubMed ID: 1381268
[TBL] [Abstract][Full Text] [Related]
4. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
5. Serum alpha-fucosidase and hexosaminidase as biological markers in human cancer.
De Martínez NR; Castro N
Medicina (B Aires); 1982; 42(1):36-42. PubMed ID: 7132700
[No Abstract] [Full Text] [Related]
6. Frequency of an allele for low activity of alpha-L-fucosidase in sera: possible increase in epithelial ovarian cancer patients.
Barlow JJ; DiCioccio RA; Dillard PH; Blumenson LE; Matta KL
J Natl Cancer Inst; 1981 Nov; 67(5):1005-9. PubMed ID: 6946242
[TBL] [Abstract][Full Text] [Related]
7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
8. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis.
Giardina MG; Matarazzo M; Morante R; Lucariello A; Varriale A; Guardasole V; De Marco G
Cancer; 1998 Dec; 83(12):2468-74. PubMed ID: 9874450
[TBL] [Abstract][Full Text] [Related]
9. Alpha-fucosidase as a marker of genetic deletion in ovarian carcinoma.
Beattie GJ; Roulston JE; Eccles DM; Richardson JM; Fisken J; Leonard RC
Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():207-8. PubMed ID: 8466157
[No Abstract] [Full Text] [Related]
10. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
Shabana A; Onsrud M
Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
[TBL] [Abstract][Full Text] [Related]
11. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
12. [Rational application of tumor marker CA 125 in gynecological oncology].
Durdević S; Stojanović S; Marijana BN; Maksimović M
Med Pregl; 2010; 63(3-4):195-9. PubMed ID: 21053460
[TBL] [Abstract][Full Text] [Related]
13. Serum fucosylation changes in oral cancer and oral precancerous conditions: alpha-L-fucosidase as a marker.
Shah M; Telang S; Raval G; Shah P; Patel PS
Cancer; 2008 Jul; 113(2):336-46. PubMed ID: 18521898
[TBL] [Abstract][Full Text] [Related]
14. Plasma alpha-L-fucosidase activity and the risk of borderline epithelial ovarian tumors.
Harlow BL; Weiss NS; Holmes EH
Cancer Res; 1990 Aug; 50(15):4702-3. PubMed ID: 2164446
[TBL] [Abstract][Full Text] [Related]
15. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
16. Rapid kinetic rate assay of the serum alpha-L-fucosidase in patients with hepatocellular carcinoma by using a novel substrate.
Wang JJ; Cao EH
Clin Chim Acta; 2004 Sep; 347(1-2):103-9. PubMed ID: 15313147
[TBL] [Abstract][Full Text] [Related]
17. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
19. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
20. Serum neopterin levels in ovarian tumors.
Park IS; Lee YS; Kim JC; Hwang SG
Int J Gynaecol Obstet; 1995 Dec; 51(3):229-34. PubMed ID: 8745088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
